Skip to content

A clinical study to see the combined effect of Pathyadi churna and Kshara basti in the management of Rheumatoid arthritis

A clinical study on the combined effectiveness of pathyadi churna and kshara basti in the management of amavata (rheumatoid arthritis)

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031002
Enrollment
30
Registered
2021-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M069- Rheumatoid arthritis, unspecified

Interventions

Intervention1: Pathyadi Churna Kshara Basti: Pathyadi churna with ingredients shunti haritaki and ajamoda in equal quantity given at a dosage 4 grams three times a day before food with warm water for

Sponsors

Sri Dharmasthala College of Ayurveda and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: subjects with features of Rheumatoid Arthritis as specified in 2010 ACR EULAR classification subjects with less than 10 years chronicity subjects fit for basti karma Subjects who signed consent form

Exclusion criteria

Exclusion criteria: Subjects with known case of essential hypertension and uncontrolled diabetes mellitus Subjects with known case of impaired renal hepatic or cardiac function Subjects with known case of systemic arthritis Pregnant and lactating woman

Design outcomes

Primary

MeasureTime frame
Lakshanas of amavata angamardha aruchi trishna alasya gaurava jwara apaka shotha shoola stabdhata of sandhiTimepoint: 15 days

Secondary

MeasureTime frame
ACR EULAR Score DAS Score Rapid 3 Score Grip Strength Foot pressureTimepoint: 15 days

Countries

India

Contacts

Public ContactDr Girish K J

Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital

drgirishkj@sdmcahhassan.org9448646855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026